Immix Biopharma, Inc.
IMMXNASDAQHealthcare● Active
$7.87
$-0.06(-0.76%)
Market Cap$428217930
P/E Ratio—
52W High$11.61
52W Low$1.94
Immix Biopharma, Inc. (IMMX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IMMX · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.18
Est. -$0.18 · +0.3%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
✓ 1-Quarter EPS Beat Streak
IMMX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 14, 2026 | -$0.19 | — | — | — | — | — |
| — Q2 FY2026 | May 7, 2026 | -$0.18 | -$0.18 | +0.3% | — | — | — |
| ▼ Q1 FY2026 | Mar 25, 2026 | -$0.21 | -$0.27 | -28.6% | — | — | — |
| ▼ Q4 FY2025 | Nov 7, 2025 | -$0.19 | -$0.24 | -26.3% | — | — | — |
| ▼ Q3 FY2025 | Aug 8, 2025 | -$0.21 | -$0.22 | -4.8% | — | — | — |
| ▲ Q2 FY2025 | May 8, 2025 | -$0.23 | -$0.15 | +34.8% | — | — | — |
| ▲ Q1 FY2025 | Mar 24, 2025 | -$0.25 | -$0.16 | +36.0% | $0.00B | — | — |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$0.16 | -$0.24 | -50.0% | — | — | — |
Q3 FY2026
Aug 14, 2026
EPS Actual
—
EPS Est.
-$0.19
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026
EPS Actual
-$0.18
EPS Est.
-$0.18
EPS Surpr.
+0.3%
Revenue
—
Q1 FY2026
Mar 25, 2026Miss
EPS Actual
-$0.27
EPS Est.
-$0.21
EPS Surpr.
-28.6%
Revenue
—
Q4 FY2025
Nov 7, 2025Miss
EPS Actual
-$0.24
EPS Est.
-$0.19
EPS Surpr.
-26.3%
Revenue
—
Q3 FY2025
Aug 8, 2025Miss
EPS Actual
-$0.22
EPS Est.
-$0.21
EPS Surpr.
-4.8%
Revenue
—
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$0.15
EPS Est.
-$0.23
EPS Surpr.
+34.8%
Revenue
—
Q1 FY2025
Mar 24, 2025Beat
EPS Actual
-$0.16
EPS Est.
-$0.25
EPS Surpr.
+36.0%
Revenue
$0.00B
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$0.24
EPS Est.
-$0.16
EPS Surpr.
-50.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.24 | $-0.24 | $-0.24 | 1 |
| Q3 FY2027 | $-0.21 | $-0.21 | $-0.21 | 1 |
| Q2 FY2027 | $-0.32 | $-0.32 | $-0.32 | 1 |
| Q1 FY2027 | $-0.24 | $-0.24 | $-0.24 | 1 |
| Q4 FY2026 | $-0.19 | $-0.19 | $-0.19 | 1 |
| Q3 FY2026 | $-0.21 | $-0.17 | $-0.14 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +0.3% | $10.32 | $9.54 | -7.56% |
| ▼ Q1 FY2026 | Mar 25, 2026 | -28.6% | $8.57 | $8.91 | +3.97% |
| ▼ Q4 FY2025 | Nov 7, 2025 | -26.3% | $3.03 | $3.15 | +3.96% |
| ▼ Q3 FY2025 | Aug 8, 2025 | -4.8% | $2.39 | $2.39 | +0.00% |
| ▲ Q2 FY2025 | May 8, 2025 | +34.8% | $2.12 | $2.15 | +1.42% |
| ▲ Q1 FY2025 | Mar 24, 2025 | +36.0% | $1.80 | $1.82 | +1.11% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -50.0% | $1.77 | $1.72 | -2.82% |
| ▲ Q3 FY2024 | Aug 12, 2024 | +28.6% | $1.95 | $1.85 | -5.13% |
Q2 FY2026-7.56%
Report Date
May 7, 2026
EPS Beat/Miss
+0.3%
Price Before
$10.32
Price After
$9.54
Q1 FY2026+3.97%
Report Date
Mar 25, 2026
EPS Beat/Miss
-28.6%
Price Before
$8.57
Price After
$8.91
Q4 FY2025+3.96%
Report Date
Nov 7, 2025
EPS Beat/Miss
-26.3%
Price Before
$3.03
Price After
$3.15
Q3 FY2025+0.00%
Report Date
Aug 8, 2025
EPS Beat/Miss
-4.8%
Price Before
$2.39
Price After
$2.39
Q2 FY2025+1.42%
Report Date
May 8, 2025
EPS Beat/Miss
+34.8%
Price Before
$2.12
Price After
$2.15
Q1 FY2025+1.11%
Report Date
Mar 24, 2025
EPS Beat/Miss
+36.0%
Price Before
$1.80
Price After
$1.82
Q4 FY2024-2.82%
Report Date
Nov 12, 2024
EPS Beat/Miss
-50.0%
Price Before
$1.77
Price After
$1.72
Q3 FY2024-5.13%
Report Date
Aug 12, 2024
EPS Beat/Miss
+28.6%
Price Before
$1.95
Price After
$1.85
Avg Beat Reaction-2.54%
Avg Miss Reaction+1.28%
Beat Rate4 / 8 quarters
Largest Move-7.56% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IMMX ends December
Immix Biopharma, Inc. (IMMX) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.18 (in line with the analyst consensus of $-0.18). The next IMMX earnings date is expected around September 1, 2026.
Each quarter, investors track IMMX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IMMX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IMMX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IMMX earnings · 4 questionsImmix Biopharma, Inc.'s next earnings report is expected around September 1, 2026. IMMX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IMMX historically reports after market close (AMC).
IMMX earnings datewhen is IMMX earningsIMMX next earnings datewhen does IMMX report earningsIMMX earnings calendar
▸ Source: FMP · Immix Biopharma, Inc. SEC filings · US GAAP · Immix Biopharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026